LianBio
LIANYLIANY · Stock Price
Historical price data
Overview
LianBio's mission was to accelerate the availability of innovative medicines for patients in China and broader Asian markets by in-licensing clinical-stage assets from global partners. The company built an integrated regional development and commercialization platform to navigate complex regulatory and commercial landscapes. Its primary achievement was advancing a portfolio of promising candidates, including mavacamten for oHCM which reached NDA acceptance in China, before the Board's decision to wind down operations and liquidate the pipeline following a strategic review in November 2023.
Technology Platform
An integrated regional development and commercialization platform designed to identify, in-license, develop, and prepare for the launch of innovative therapeutics in China and Asia-Pacific markets.
Pipeline
7| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Mavacamten + Placebo | Obstructive Hypertrophic Cardiomyopathy | Phase 3 | |
| Lotilaner + Vehicle Control | Blepharitis | Phase 3 | |
| Infigratinib | Gastric Cancer | Phase 2 | |
| Infigratinib | Gastric Cancer | Phase 2 | |
| Mavacamten | Hypertrophic Cardiomyopathy | Phase 1 |
Opportunities
Risk Factors
Competitive Landscape
LianBio competed with large multinational pharma, established China-focused biopharmas (e.g., Zai Lab, Innovent), and other licensing-focused biotechs. Its relatively late entry and lack of commercial scale in a crowded field presented significant challenges to its standalone sustainability.